127 related articles for article (PubMed ID: 19543928)
1. Molecular-docking-guided 3D-QSAR studies of substituted isoquinoline-1,3-(2H,4H)-diones as cyclin-dependent kinase 4 (CDK4) inhibitors.
Lu XY; Chen YD; Sun NY; Jiang YJ; You QD
J Mol Model; 2010 Feb; 16(2):163-73. PubMed ID: 19543928
[TBL] [Abstract][Full Text] [Related]
2. 4-(Phenylaminomethylene)isoquinoline-1,3(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4 (CDK4).
Tsou HR; Otteng M; Tran T; Floyd MB; Reich M; Birnberg G; Kutterer K; Ayral-Kaloustian S; Ravi M; Nilakantan R; Grillo M; McGinnis JP; Rabindran SK
J Med Chem; 2008 Jun; 51(12):3507-25. PubMed ID: 18494457
[TBL] [Abstract][Full Text] [Related]
3. Insight into the interactions between novel isoquinolin-1,3-dione derivatives and cyclin-dependent kinase 4 combining QSAR and molecular docking.
Zheng J; Kong H; Wilson JM; Guo J; Chang Y; Yang M; Xiao G; Sun P
PLoS One; 2014; 9(4):e93704. PubMed ID: 24722522
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 4-(benzylaminomethylene)isoquinoline-1,3-(2H,4H)-diones and 4-[(pyridylmethyl)aminomethylene]isoquinoline-1,3-(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4.
Tsou HR; Liu X; Birnberg G; Kaplan J; Otteng M; Tran T; Kutterer K; Tang Z; Suayan R; Zask A; Ravi M; Bretz A; Grillo M; McGinnis JP; Rabindran SK; Ayral-Kaloustian S; Mansour TS
J Med Chem; 2009 Apr; 52(8):2289-310. PubMed ID: 19317452
[TBL] [Abstract][Full Text] [Related]
5. Global, local and novel consensus quantitative structure-activity relationship studies of 4-(Phenylaminomethylene) isoquinoline-1, 3 (2H, 4H)-diones as potent inhibitors of the cyclin-dependent kinase 4.
Lei B; Xi L; Li J; Liu H; Yao X
Anal Chim Acta; 2009 Jun; 644(1-2):17-24. PubMed ID: 19463556
[TBL] [Abstract][Full Text] [Related]
6. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
[TBL] [Abstract][Full Text] [Related]
7. Structural requirements of pyrido[2,3-d]pyrimidin-7-one as CDK4/D inhibitors: 2D autocorrelation, CoMFA and CoMSIA analyses.
Caballero J; Fernández M; González-Nilo FD
Bioorg Med Chem; 2008 Jun; 16(11):6103-15. PubMed ID: 18468903
[TBL] [Abstract][Full Text] [Related]
8. 3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: an insight into the criteria for selectivity.
Dessalew N; Bharatam PV
Eur J Med Chem; 2007 Jul; 42(7):1014-27. PubMed ID: 17335939
[TBL] [Abstract][Full Text] [Related]
9. Molecular modeling studies of [4-(3
Lv H; Du Y; Sheng X; Gao Z; Shen J
Future Med Chem; 2021 Aug; 13(16):1317-1339. PubMed ID: 34210159
[No Abstract] [Full Text] [Related]
10. 3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors.
Singh SK; Dessalew N; Bharatam PV
Eur J Med Chem; 2006 Nov; 41(11):1310-9. PubMed ID: 16890327
[TBL] [Abstract][Full Text] [Related]
11. 3D-QSAR studies of Checkpoint Kinase Weel inhibitors based on molecular docking, CoMFA and CoMSIA.
Yi P; Fang X; Qiu M
Eur J Med Chem; 2008 May; 43(5):925-38. PubMed ID: 17698256
[TBL] [Abstract][Full Text] [Related]
12. 3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies.
Thaimattam R; Daga P; Rajjak SA; Banerjee R; Iqbal J
Bioorg Med Chem; 2004 Dec; 12(24):6415-25. PubMed ID: 15556759
[TBL] [Abstract][Full Text] [Related]
13. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
14. 3D-QSAR and 3D-QSSR studies of thieno[2,3-d]pyrimidin-4-yl hydrazone analogues as CDK4 inhibitors by CoMFA analysis.
Cai BQ; Jin HX; Yan XJ; Zhu P; Hu GX
Acta Pharmacol Sin; 2014 Jan; 35(1):151-60. PubMed ID: 24122012
[TBL] [Abstract][Full Text] [Related]
15. Selective ATP competitive leads of CDK4: Discovery by 3D-QSAR pharmacophore mapping and molecular docking approach.
Rondla R; PadmaRao LS; Ramatenki V; Haredi-Abdel-Monsef A; Potlapally SR; Vuruputuri U
Comput Biol Chem; 2017 Dec; 71():224-229. PubMed ID: 29153893
[TBL] [Abstract][Full Text] [Related]
16. Structural requirements of isoquinolones as novel selective c-Jun N-terminal kinase 1 inhibitors: 2D and 3D QSAR analyses.
Du J; Xi L; Lei B; Liu H; Yao X
Chem Biol Drug Des; 2011 Apr; 77(4):248-54. PubMed ID: 21276204
[TBL] [Abstract][Full Text] [Related]
17. Identification of the Structural Features of Guanine Derivatives as MGMT Inhibitors Using 3D-QSAR Modeling Combined with Molecular Docking.
Sun G; Fan T; Zhang N; Ren T; Zhao L; Zhong R
Molecules; 2016 Jun; 21(7):. PubMed ID: 27347909
[TBL] [Abstract][Full Text] [Related]
18. Molecular docking guided 3D-QSAR CoMFA analysis of N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of leukocyte-specific protein tyrosine kinase.
Awale M; Mohan CG
J Mol Model; 2008 Oct; 14(10):937-47. PubMed ID: 18626671
[TBL] [Abstract][Full Text] [Related]
19. CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site.
Buolamwini JK; Assefa H
J Med Chem; 2002 Feb; 45(4):841-52. PubMed ID: 11831895
[TBL] [Abstract][Full Text] [Related]
20. 3D-QSAR and docking studies on pyrazolo[4,3-h]qinazoline-3-carboxamides as cyclin-dependent kinase 2 (CDK2) inhibitors.
Lan P; Chen WN; Xiao GK; Sun PH; Chen WM
Bioorg Med Chem Lett; 2010 Nov; 20(22):6764-72. PubMed ID: 20869873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]